BBIO BridgeBio Pharma, Inc.: institutional ownership and insider trading
509 funds reported holding $17.9B of BridgeBio Pharma, Inc. in their latest 13F filings; in Q2 2026 funds net sold $78.7M, with 80 new positions and 69 funds selling out; over the last 12 months insiders bought $0 and sold $118M on the open market; over its last four quarters it reported revenue of $713M and net income of −$702M.
BBIO revenue and earnings
- Quarter ended Jun 30, 2026: revenue $244M, net income −$156M, EPS -0.78
- Quarter ended Mar 31, 2026: revenue $195M, net income −$167M, EPS -0.84
- Quarter ended Dec 31, 2025: revenue $154M, net income −$195M, EPS -1.00
- Quarter ended Sep 30, 2025: revenue $121M, net income −$185M, EPS -0.95
Famous investors holding BBIO
- Andreas Halvorsen (Viking Global Investors): $741M, 2.1% of the portfolio
- Two Sigma (Two Sigma Investments): $353M, 0.3% of the portfolio
- Ray Dalio (Bridgewater Associates): $33.4M, 0.1% of the portfolio
- D. E. Shaw (D. E. Shaw & Co.): $273M, 0.1% of the portfolio
- Renaissance Technologies (Renaissance Technologies): $63.8M, 0.1% of the portfolio
- Ken Griffin (Citadel Advisors): $322M, 0.0% of the portfolio
- Izzy Englander (Millennium Management): $49.9M, 0.0% of the portfolio
Largest institutional holders of BBIO
- VANGUARD GROUP INC — $1.29B
- Jupiter Topco LLC — $1.05B
- Kohlberg Kravis Roberts & Co. L.P. — $988M
- JANUS HENDERSON GROUP PLC (JHG) — $979M
- FARALLON CAPITAL MANAGEMENT, L.L.C. — $800M
- BlackRock, Inc. (BLK) — $766M
- VIKING GLOBAL INVESTORS LP — $741M
- VANGUARD CAPITAL MANAGEMENT LLC — $588M
- VANGUARD PORTFOLIO MANAGEMENT LLC — $570M
- JANE STREET GROUP, LLC — $455M
Recent BBIO insider trades
- Sep 17, 2026: Kumar Neil sold 10,000 shares ($691K)
- Aug 19, 2026: Kumar Neil sold 44,980 shares ($3.73M)
- Jul 30, 2026: Apuli Maricel sold 2,000 shares ($160K)
- Jul 9, 2026: Cook Jennifer E. sold 148,589 shares ($13.2M)
Members of Congress trading BBIO
- Sep 29, 2026: Gilbert Ray Cisneros, Jr. sold part of $1.00K–$15.0K
- May 11, 2026: Gilbert Ray Cisneros, Jr. bought $1.00K–$15.0K
- Apr 29, 2026: Gilbert Ray Cisneros, Jr. bought $1.00K–$15.0K
- Mar 19, 2026: Gilbert Ray Cisneros, Jr. bought $1.00K–$15.0K
- Mar 18, 2026: Gilbert Ray Cisneros, Jr. bought $1.00K–$15.0K
- Mar 3, 2026: Gilbert Ray Cisneros, Jr. bought $1.00K–$15.0K
- Sep 22, 2025: Gilbert Ray Cisneros, Jr. bought $1.00K–$15.0K
- Aug 8, 2025: Gilbert Ray Cisneros, Jr. bought $1.00K–$15.0K
5%+ owners
- JANUS HENDERSON GROUP PLC: 6.8% (Schedule 13G/A, filed May 15, 2026)
- Farallon Capital Management, L.L.C.: 5.5% (Schedule 13G/A, filed Aug 3, 2026)
- Dapice Joshua J.: 5.2% (Schedule 13G, filed May 29, 2026)
- VIKING GLOBAL INVESTORS LP: 5.0% (Schedule 13D/A, filed Jul 10, 2026)
Who owns the most BBIO stock?
The largest institutional holders of BridgeBio Pharma, Inc. in the latest 13F filings are VANGUARD GROUP INC ($1.29B), Jupiter Topco LLC ($1.05B), Kohlberg Kravis Roberts & Co. L.P. ($988M).
Are insiders buying or selling BBIO?
Over the last 12 months insiders bought $0 and sold $118M of BridgeBio Pharma, Inc. stock on the open market (SEC Form 4).
Which famous investors own BBIO?
Andreas Halvorsen, Two Sigma, Ray Dalio, D. E. Shaw, Renaissance Technologies.
What was BBIO's revenue last quarter?
BridgeBio Pharma, Inc. reported revenue of $244M for the quarter ended June 30, 2026, with net income of −$156M.
Which ETFs hold BBIO?
165 ETFs and mutual funds hold it among their top 100 positions, including VGHAX, VBK, JAENX, VEXPX.